ImmunityBio Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2013
Revenue	0.62	0.24	0.93	0.61	2.2	Upgrade
Revenue Growth (YoY)	159.17%	-74.30%	54.38%	-72.52%	4585.11%	Upgrade
Gross Profit	0.62	0.24	0.93	0.61	2.2	Upgrade
Selling, General & Admin	129.62	102.71	135.26	71.32	46.46	Upgrade
Research & Development	232.37	248.15	195.96	139.51	112	Upgrade
Other Operating Expenses	0.89	0.68	0	10.66	0	Upgrade
Operating Expenses	362.87	351.54	331.21	221.49	158.45	Upgrade
Operating Income	-362.25	-351.3	-330.28	-220.88	-156.25	Upgrade
Interest Expense / Income	129.2	63.52	14.85	9.07	5.92	Upgrade
Other Expense / Income	91.79	1.72	1.65	-6.26	-4.29	Upgrade
Pretax Income	-583.24	-416.53	-346.78	-223.7	-157.88	Upgrade
Income Tax	-0.04	0.03	0.01	-1.85	-0.11	Upgrade
Net Income	-583.2	-416.57	-346.79	-221.85	-157.78	Upgrade
Shares Outstanding (Basic)	509	400	389	377	366	Upgrade
Shares Outstanding (Diluted)	509	400	389	377	366	Upgrade
Shares Change	27.19%	2.74%	3.23%	2.93%	362.93%	Upgrade
EPS (Basic)	-1.15	-1.04	-0.89	-0.59	-0.43	Upgrade
EPS (Diluted)	-1.15	-1.04	-0.89	-0.59	-0.43	Upgrade
Free Cash Flow	-397.34	-415.67	-287.48	-173.39	-156.2	Upgrade
Free Cash Flow Per Share	-0.78	-1.04	-0.74	-0.46	-0.43	Upgrade
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	Upgrade
Operating Margin	-58239.55%	-146374.17%	-35361.88%	-36509.09%	-7095.87%	Upgrade
Profit Margin	-93761.41%	-173569.58%	-37129.55%	-36669.59%	-7165.17%	Upgrade
Free Cash Flow Margin	-63881.19%	-173196.25%	-30779.87%	-28660.00%	-7093.37%	Upgrade
EBITDA	-429.41	-328.83	-312.81	-196.73	-133.79	Upgrade
EBITDA Margin	-69037.62%	-137010.83%	-33491.43%	-32517.19%	-6075.79%	Upgrade
Depreciation & Amortization	24.62	24.19	19.12	17.89	18.17	Upgrade
EBIT	-454.04	-353.02	-331.93	-214.62	-151.96	Upgrade
EBIT Margin	-72996.46%	-147090.83%	-35538.76%	-35474.88%	-6901.09%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).